How Bridge Programs Support Patients During Coverage Delays

A prescription does not always lead directly to treatment. For specialty therapies, patients may encounter prior authorization requirements, insurance changes, benefit verification, formulary reviews, or other coverage issues before a payer will cover the medication. A systematic review of 44 studies found that prior authorization was associated with significant delays in starting specialty medications, and recent physician survey data continues to show that authorization requirements can delay or even contribute to abandonment of care. Bridge programs in pharmaceuticals can help address a specific part of this problem by providing eligible patients with temporary access to medication while a coverage issue is being resolved.

What Are Bridge Programs in Pharmaceuticals?

A bridge program is a temporary access arrangement that can provide medication at no or reduced cost during a defined gap in insurance coverage. Depending on the program, that gap might occur while a patient waits for a prior authorization decision, appeals a coverage denial, changes insurance plans, or experiences another short-term interruption in coverage. Current manufacturer programs show that bridge support may be used either to help an eligible new patient begin treatment or to help someone already receiving therapy avoid an interruption.

The word “bridge” is important. These programs are generally designed to connect one point of access to another, rather than replace insurance coverage on an ongoing basis. Some programs specifically require the patient and healthcare provider to continue pursuing insurance approval while temporary medication is supplied.

That makes bridge programs different from other forms of pharmaceutical assistance. A co-pay program may reduce the out-of-pocket expense for an eligible commercially insured patient, while a patient assistance program may provide free medication to qualifying uninsured or underinsured patients. Bridge support instead addresses a temporary coverage delay or interruption. The eligibility criteria and purpose of each type of assistance can be different even when the programs are offered through the same patient support organization.

Coverage Delays Can Occur at Different Points

Prior authorization is one of the clearest situations in which temporary access may be useful. In a 2025 survey of 1,000 practicing physicians, 95% reported that prior authorization delays patients’ access to necessary care, while physicians and their staff reported spending an average of 13 hours per week completing authorization requirements.

But a coverage delay does not always happen at the beginning of treatment. A patient who has been stable on a therapy might change employers or insurance plans. An existing authorization may expire. A payer may change its coverage requirements. An insurance transition can create a period in which the next refill or dose is uncertain even though the patient and prescriber intend to continue treatment.

Manufacturer programs reflect these different situations. Some provide temporary access specifically for new patients awaiting an insurance decision, while others reserve their bridge benefit for patients already on treatment who experience a change or interruption in coverage. Some manufacturers distinguish between a “quick start” program for treatment initiation and a “bridge” program for continuity during an insurance disruption.

Eligibility and Program Limits Matter

There is no single eligibility standard for pharmaceutical bridge programs. Current program terms vary substantially by product. Some require commercial insurance, a valid prescription, and evidence of a pending or denied prior authorization. Other programs may cover particular insurance changes or temporary lapses. Certain programs exclude patients whose prescriptions are reimbursed through Medicare, Medicaid, or other government-funded healthcare programs.

Duration also varies. One current program provides eligible patients with up to four months of temporary medication, another provides up to two 14-day supplies for a coverage interruption, and other programs may extend temporary access considerably longer while defined insurance requirements continue to be met.

These differences make it important to evaluate eligibility at the individual patient level rather than treating bridge access as an automatic benefit. Programs can have enrollment requirements, deadlines, re-verification requirements, limits on repeat use, and rules governing what must happen while insurance coverage is pursued. Manufacturers may also modify or discontinue program terms.

Temporary Access Should Not Stop the Coverage Process

Receiving a temporary supply solves an immediate access problem, but it does not necessarily resolve the underlying coverage issue. The prior authorization, appeal, benefit investigation, or insurance transition may still need to continue.

This is where bridge programs fit into a broader commercial patient support workflow. A patient support team may need to know when the temporary supply began, how much medication remains, what action the payer is waiting for, whether additional documentation is required, and when the bridge benefit will end. Current manufacturer programs sometimes make continued eligibility dependent on submitting an authorization request or appeal within a specified period, illustrating how temporary access and reimbursement work can run in parallel.

Operationally, this means the bridge should be treated as one stage of the access journey, not the endpoint. The intended progression is from a coverage delay, to temporary access when the patient qualifies, to resolution of the payer process and a sustainable source of coverage. For longer-term coverage problems, a different assistance pathway may need to be considered if the patient meets that program’s eligibility requirements. Research describing specialty pharmacy transitions has similarly distinguished temporary bridge support during short coverage lapses from patient assistance programs used for longer interruptions.

Keeping the Patient Connected During the Gap

Coverage delays are administrative, but patients experience them personally. Someone who has already received a prescription may not understand why treatment has not started, whether medication will arrive before the next dose, or what happens when temporary assistance ends. Clear communication is therefore an important part of the bridge process.

A well-coordinated program can keep the patient, provider, reimbursement team, and dispensing pharmacy aligned on the same next step while the underlying insurance issue moves toward resolution. Bridge programs do not eliminate prior authorization or guarantee future coverage. Their value is narrower but meaningful: when appropriately designed and used for eligible patients, they can create a temporary path across a coverage gap instead of allowing that gap to become an avoidable interruption in therapy.

Prescription
Pre-screen
Benefits Investigation
Prior Authorization
Affordability Support
Specialty Pharmacy Coordination
Follow-up
Therapy Start


This continuity becomes particularly important when something changes. A payer may request additional information. An authorization may be denied. A patient’s coverage may change. A specialty pharmacy may need clarification before dispensing. Follow-up gives the access team an opportunity to identify those issues while there is still a clear next action.

The broader direction of reimbursement administration also points toward greater workflow integration. CMS has finalized interoperability requirements intended to streamline prior authorization for many medical items and services, and in 2026 proposed extending similar electronic prior authorization capabilities to drugs covered under medical benefits. The proposal reflects the continuing industry focus on reducing fragmented documentation and improving the speed and transparency of authorization workflows.

For specialty therapies, the important lesson is that reimbursement is not one administrative event. It is a sequence of dependent steps. Reimbursement support services can help make those steps visible, organized, and connected so patients, providers, pharmacies, and support teams know what needs to happen next.

Practical Recommendations

For organizations designing or evaluating a reimbursement support model, three practices deserve particular attention:

  1. Establish the coverage pathway early. Confirm the applicable benefit, payer requirements, authorization needs, and likely patient cost exposure before the case moves through multiple downstream teams. Early, accurate benefit identification as an opportunity to reduce duplication and delays.

  2. Treat prior authorization and appeals as one continuous workflow. Build status tracking, documentation requirements, denial reasons, deadlines, and provider follow-up into the same case process rather than treating an appeal as an entirely new transaction. CMS’s prior authorization initiatives similarly emphasize better information exchange and greater process transparency.

  3. Measure the handoffs, not only completed tasks. Track whether a patient successfully progresses from benefits investigation to authorization, affordability support, pharmacy coordination, and ultimately therapy start. Delays can arise at multiple points, including communication, authorization, formulary, financial assistance, and pharmacy fulfillment.

 

Don’t Miss a Post — Subscribe to Our Insights!